Kenneth A. Bauer
#133,757
Most Influential Person Now
Kenneth A. Bauer's AcademicInfluence.com Rankings
Kenneth A. Bauerphilosophy Degrees
Philosophy
#6649
World Rank
#9717
Historical Rank
Logic
#3782
World Rank
#4991
Historical Rank

Download Badge
Philosophy
Why Is Kenneth A. Bauer Influential?
(Suggest an Edit or Addition)Kenneth A. Bauer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Extrapulmonary manifestations of COVID-19 (2020) (1998)
- Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial (2009) (958)
- Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. (2002) (752)
- Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (725)
- Activation of coagulation after administration of tumor necrosis factor to normal subjects. (1990) (710)
- Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) (681)
- Inherited Thrombophilia: Part 1 (1996) (637)
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. (2001) (630)
- Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. (2001) (626)
- Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction (1994) (611)
- Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial (2002) (499)
- Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy (2009) (467)
- Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. (1994) (452)
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. (2018) (429)
- The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. (1987) (424)
- Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer (2019) (322)
- Inherited Thrombophilia*: Part 2 (1996) (308)
- BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study (2005) (306)
- Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. (1982) (275)
- Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison (2002) (250)
- Factor V Leiden (FV R506Q) in Families with Inherited Antithrombin Deficiency (1996) (244)
- Hypercoagulability in centenarians: the paradox of successful aging. (1995) (243)
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery (2008) (237)
- Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia (2004) (231)
- The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. (1989) (227)
- Coagulation Activation Following Estrogen Administration to Postmenopausal Women (1992) (226)
- The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. (1993) (222)
- Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. (2012) (220)
- Pros and cons of new oral anticoagulants. (2013) (216)
- Factor IX is activated in vivo by the tissue factor mechanism. (1990) (215)
- Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. (1987) (206)
- Increased Activation of the Haemostatic System in Men at High Risk of Fatal Coronary Heart Disease (1996) (202)
- Guidance for the evaluation and treatment of hereditary and acquired thrombophilia (2016) (202)
- Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis (2012) (188)
- Respiratory muscle strength in congestive heart failure. (1990) (184)
- Comparison of Novel Hemostatic Factors and Conventional Risk Factors for Prediction of Coronary Heart Disease (2000) (182)
- Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. (1989) (170)
- A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) (2008) (167)
- Postdischarge thrombosis and hemorrhage in patients with COVID-19 (2020) (162)
- Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. (2006) (159)
- The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
- Thrombin generation in acute promyelocytic leukemia. (1984) (152)
- Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study) (2013) (138)
- DETECTION OF FACTOR X ACTIVATION IN HUMANS (1989) (134)
- Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison (2007) (132)
- D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. (2015) (127)
- Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. (1990) (127)
- Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. (2002) (127)
- Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V (1994) (125)
- Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. (1987) (123)
- The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men (1995) (119)
- Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH (2012) (117)
- Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. (1988) (116)
- Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. (1985) (114)
- Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. (1989) (108)
- The plasma kallikrein–kinin system and risk of cardiovascular disease in men (2007) (104)
- The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. (1997) (103)
- New Anticoagulants: Anti IIa vs Anti Xa—Is One Better? (2006) (102)
- Activation of the Coagulant Pathway in Cigarette Smokers (1998) (100)
- Detection of protein C activation in humans. (1984) (96)
- Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. (1983) (96)
- Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa (2011) (95)
- In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. (1996) (95)
- Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects (2001) (93)
- Molecular heterogeneity of inherited antithrombin III deficiency. (1983) (92)
- Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway (2004) (92)
- Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events (2005) (92)
- Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. (1994) (92)
- Low Prevalence of the Factor V Leiden Mutation Among “Severe” Hemophiliacs with a “Milder” Bleeding Diathesis (1995) (89)
- Venous thrombosis in the elderly: more questions than answers. (2007) (88)
- Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. (1995) (86)
- Reversal of antithrombotic agents (2012) (86)
- Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism trial (2006) (84)
- Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C‐deficient family (2004) (83)
- Role of antithrombin III as a regulator of in vivo coagulation. (1991) (82)
- D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism (2006) (81)
- Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. (1990) (81)
- Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. (2019) (80)
- Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction (2000) (78)
- Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies (2007) (77)
- Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. (2004) (74)
- Laboratory markers of coagulation activation. (1993) (71)
- Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. (1993) (70)
- Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. (1992) (70)
- Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19 (2021) (69)
- Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. (1983) (69)
- Recombinant factor VIIa for the treatment of congenital factor VII deficiency. (2000) (68)
- EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. (2005) (66)
- Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. (1992) (66)
- Thrombogenic potential of human coronary atherosclerotic plaques. (2001) (65)
- Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease (1992) (63)
- Molecular analysis of Polish patients with factor VII deficiency. (1994) (61)
- Fondaparinux sodium: a selective inhibitor of factor Xa. (2001) (60)
- Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration (2003) (60)
- Coagulation activation and long-term outcome in acute coronary syndromes. (2003) (60)
- Hypercoagulability: too many tests, too much conflicting data. (2002) (59)
- No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate (1991) (59)
- Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. (1997) (58)
- Acute aortic thrombosis in antithrombin III deficiency. (1981) (58)
- The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. (2006) (57)
- Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
- Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. (1994) (56)
- Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
- Management of Patients with Hereditary Defects Predisposing to Thrombosis Including Pregnant Women (1995) (54)
- Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. (1997) (54)
- Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
- New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. (2003) (51)
- Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. (2007) (49)
- Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID‐19 (2020) (49)
- Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. (2018) (49)
- Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. (1993) (48)
- Fondaparinux, the first selective factor Xa inhibitor (2003) (48)
- Treatment of factor VII deficiency with recombinant factor VIIa. (1996) (48)
- Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures (2003) (48)
- Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. (1987) (47)
- Activation markers of coagulation. (1994) (45)
- A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. (1992) (45)
- Risk of Intracranial Hemorrhage in Ground‐level Fall With Antiplatelet or Anticoagulant Agents (2017) (44)
- Measures to assess the prognostic ability of the stratified Cox proportional hazards model (2009) (44)
- Heparin induced thrombocytopenia antibodies in Covid‐19 (2020) (44)
- Management of thrombophilia (2003) (43)
- A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. (1996) (43)
- Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. (1991) (43)
- A functional haplotype in the 5′ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease (2003) (42)
- A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. (2002) (42)
- Coagulation activation and long-term outcome in acute coronary syndromes Running title: Coagulation activation and long-term outcome in CHD Section heading: Clinical observation (2003) (42)
- Haemostatic changes that constitute the hypercoagulable state (1991) (40)
- Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: A summary of case reports (1995) (40)
- Hypercoagulability--a new cofactor in the protein C anticoagulant pathway. (1994) (40)
- New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. (2003) (39)
- Parenteral Anticoagulants (2008) (38)
- A chromogenic assay for activated protein C resistance (1995) (37)
- Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency (2016) (37)
- Recombinant Nematode Anticoagulant Protein c2, a Novel Inhibitor of Tissue Factor-Factor VIIa Activity, Abrogates Endotoxin-Induced Coagulation in Chimpanzees (2002) (36)
- Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter. (1998) (36)
- Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. (1995) (36)
- Targeted Anti-Anticoagulants. (2015) (35)
- Coumarin-induced skin necrosis. (1993) (35)
- L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. (1983) (34)
- Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency (2013) (34)
- Initiation of a Multidisciplinary, Rapid Response Team to Massive and Submassive Pulmonary Embolism. (2017) (32)
- Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review (2010) (32)
- Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency. (2004) (31)
- Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. (1993) (31)
- The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. (2014) (31)
- Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces. (1985) (31)
- Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency (1993) (30)
- Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. (1999) (29)
- FVII, FVIIa, and Downstream Markers of Extrinsic Pathway Activation Differ by EPCR Ser219Gly Variant in Healthy Men (2009) (29)
- Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). (2008) (28)
- Activation of the Factor VII-Tissue Factor Pathway (1997) (28)
- Thrombophilias in pregnancy. (2011) (28)
- Thrombin generation in non-cardioembolic stroke subtypes (2004) (27)
- The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. (2010) (27)
- Expression and characterization of human antithrombin III synthesized in mammalian cells. (1987) (27)
- Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery (1994) (27)
- Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study (2019) (27)
- Protease inhibitors of human plasma. Antithrombin-III. "The heparin-antithrombin system". (1985) (26)
- Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. (2010) (26)
- The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency (2004) (26)
- Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. (2004) (25)
- COMPARISON OF RIVAROXABAN – AN ORAL, DIRECT FACTOR XA INHIBITOR–AND SUBCUTANEOUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT (RECORD4: A PHASE III STUDY) (2010) (25)
- Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations (2000) (25)
- In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris (2000) (25)
- Effect of Low‐Intensity Warfarin Anticoagulation on Level of Activity of the Hemostatic System in Patients With Atrial Fibrillation (1993) (23)
- The G20210A Prothrombin Polymorphism Is not Associated with Increased Thromboembolic Risk in a Large Protein C Deficient Kindred (2000) (23)
- A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency. (2000) (23)
- Management of hereditary antithrombin deficiency in pregnancy. (2017) (23)
- Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI) (2018) (22)
- Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. (1989) (22)
- Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review (2004) (22)
- New markers for in vivo coagulation. (1994) (22)
- Factor XIa Induced Activation of the Intrinsic Cascade In Vivo (1996) (21)
- Selective inhibition of coagulation factors: advances in antithrombotic therapy. (2002) (21)
- Dysfunctional Activated Protein C (PC Cádiz) in a Patient with Thrombotic Disease (1987) (20)
- Polymorphisms in the factor VII gene and ischemic stroke in young adults (2010) (20)
- Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene. (1999) (20)
- DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. (2020) (20)
- Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men (2010) (20)
- Role of thrombophilia in deciding on the duration of anticoagulation. (2004) (19)
- Determinants of plasma factor VIIa levels in humans. (1995) (19)
- F9 Malmö, factor IX and deep vein thrombosis (2009) (19)
- Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery (2003) (19)
- Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4 (2008) (19)
- Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation. (1989) (18)
- Timing of postpartum enoxaparin administration and severe postpartum hemorrhage (2008) (18)
- Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban (2019) (18)
- Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. (2020) (17)
- Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. (1999) (17)
- Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery (2008) (17)
- Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization. (1991) (16)
- Managing Thromboembolic Risk in Patients with Hereditary and Acquired Thrombophilias. (2020) (16)
- Stroke Prevention in Atrial Fibrillation in Older Adults: Existing Knowledge Gaps and Areas for Innovation: A Summary of an American Federation for Aging Research Seminar (2013) (16)
- Venous thromboembolism in malignancy. (2000) (16)
- D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. (2016) (15)
- Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur (2003) (15)
- Determination of Free Haemoglobin in Serum by an Automated Assay Using 4-Aminophenazone and the Cobas Bio System (1981) (15)
- Prothrombin activation fragment assay. (1993) (15)
- Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. (2001) (14)
- Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. (2020) (14)
- Changes in Care for Acute Pulmonary Embolism with a Multidisciplinary Pulmonary Embolism Response Team: PE Response Team. (2020) (14)
- Current challenges in the management of hemophilia. (2015) (13)
- Duration of anticoagulation: applying the guidelines and beyond. (2010) (13)
- Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. (2021) (13)
- Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. (1995) (13)
- Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma. (1987) (13)
- International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis (2016) (13)
- Fondaparinux Combined with Intermittent Pneumatic Compression (IPC) Versus IPC Alone in the Prevention of Venous Thromboembolism after Major Abdominal Surgery: The Randomized APOLLO Study. (2005) (12)
- Asymptomatic factor VII deficiency in African Americans. (2006) (12)
- Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery (2003) (12)
- Determinants of plasma factor VIIa levels in humans (1995) (11)
- How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. (2014) (11)
- Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States (2020) (11)
- Trousseau’s Syndrome Revisited: Tissue Factor-Bearing Microparticles in Pancreatic Cancer. (2005) (11)
- New insights into hypercoagulable states. (1986) (10)
- Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery (2003) (10)
- A simple, automated functional assay for protein C. (1989) (10)
- Automated detection of the factor V Leiden mutation using the LCx microparticle enzyme immunoassay. (1999) (10)
- Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study: 121 (2019) (10)
- Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. (2002) (10)
- Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism. (2011) (9)
- Detection of a prethrombotic state (1994) (9)
- Hormone replacement therapy and the factor V Leiden mutation. (2002) (9)
- Conventional Fibrinolytic Assays for the Evaluation of Patients with Venous Thrombosis: Don’t Bother (2001) (8)
- Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis. (2009) (8)
- Targeted inhibition of coagulation: oral agents show promise in phase III trials (2007) (8)
- Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. (1985) (8)
- Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. (2013) (7)
- ARP1 interacts with the 5′ flanking region of the coagulation factor VII gene (2003) (7)
- Does a prethrombotic state exist? If so, what is it? (1992) (7)
- Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation (1999) (7)
- Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism (2002) (6)
- Interaction of factor V Leiden with inherited anti-thrombin deficiency (1995) (6)
- Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay. (2001) (6)
- Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. (2013) (6)
- Case records of the Massachusetts General Hospital. Weekly Clinicopathological Exercises. Case 12-1996. An 18-year-old woman with hepatomegaly and ascites. (1996) (6)
- New oral anticoagulants in development: potential for improved safety profiles. (2010) (6)
- Use of thromboelastography in the management of a patient with acquired von Willebrand disease undergoing cardiac bypass surgery (2018) (5)
- F 9 Malmö , factor IX and deep vein thrombosis (5)
- Does Inflammatory Proteolytic Activity Contribute to the Increased Factor IX Activation Peptide in Men at High Risk of Coronary Heart Disease? A Preliminary Study (2002) (5)
- O1067 INFLUENCE OF THE DURATION OF FONDAPARINUX PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY (2004) (4)
- How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis? (2020) (4)
- New anticoagulants. (2006) (4)
- Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College (2008) (3)
- The role of other hemostatic factors in predicting arterial thrombotic events. (2006) (3)
- Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity (2002) (3)
- Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor: Pooled results of two phase Iib clinical trials. (2005) (3)
- Increased incidence of neoplasia with persistent activation of the of the digestive tract in men coagulant pathway (2004) (3)
- CHAPTER 37 – The Level of Activity of the Hemostatic System, the Rate of Embolic Stroke, and Age: Is There a Correlation? (1995) (3)
- New anticoagulants (2008) (2)
- Low intensity warfarin: is it clinically useful in venous thromboembolism management? (2004) (2)
- Functional tissue factor in blood (2005) (2)
- Thrombophilia: Clinical and Laboratory Assessment and Management (2019) (2)
- Malmö , factor IX and deep vein thrombosis (2009) (2)
- Thrombolytic therapy in acute venous thromboembolism. (2020) (2)
- Determinants of coagulation activation in humans. (1996) (2)
- How to detect activated coagulation (1996) (2)
- Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. (2022) (2)
- Pentasaccharide (fondaparinux, Arixtra) versus enoxaparin for the prevention of venous thromboembolism (VTE) in major orthopedic surgery: subgroup analyses of efficacy (2003) (2)
- Effect on efficacy and safety of the timing of the first pentasaccharide administration in the prevention of venous thromboembolism (2001) (1)
- Coronary Heart Disease / Myocardial Infarction Diminished Vascular Response to Inhibition of Endothelium-Derived Nitric Oxide and Enhanced Vasoconstriction to Exogenously Administered Endothelin-1 in Clinically Healthy Smokers (2005) (1)
- Subject Index, Vol. 26 (suppl 1), 1996 (1996) (1)
- The challenge of hospital-related thrombosis. (2017) (1)
- TFPI and venous thrombosis (2003) (1)
- Activation markers of coagulation. (1999) (1)
- Overview and research opportunities (1992) (1)
- Progestin-Only Contraceptives and the Risk of Venous Thromboembolism: Systematic Review and Meta-Analysis, (2011) (1)
- Aspirin thromboprophylaxis in joint replacement surgery (2022) (1)
- Professor Stanislaw Lopaciuk (1935–2003) (2004) (1)
- Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study) (2018) (1)
- A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. (2002) (1)
- Hemostatic markers and prognosis in ischemic heart disease. (2001) (0)
- ACTIVATION OF EXTRINSIC COAGULATION PATHWAY IN HEALTH THAT INDEPENDENTLY PREDICTS LATER ONSET OF HEART DISEASE, IS MODIFIED BY GENOTYPE (2008) (0)
- O1062 ELASTIC STOCKINGS DO NOT INFLUENCE SUPERIOR EFFICACY OF FONDAPARINUX OVER ENOXAPARIN FOR THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY (2004) (0)
- Efficacy of Fondaparinux for Thromboprophylaxis in High-risk Patients Undergoing Hip Fracture Surger (2003) (0)
- Abstract 72: Procedural and Long Term Safety of PFO Closure in Cryptogenic Stroke: Insights from the RESPECT Trial (2017) (0)
- A Balancing Act. (2020) (0)
- Timing and Safety of Postpartum Enoxparin. (2006) (0)
- O1063 EFFECT ON EFFICACY AND SAFETY OF THE TIMING OF THE FIRST FONDAPARINUX ADMINISTRATION FOR THE THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY (2004) (0)
- O1064 MANAGEMENT OF ORTHOPEDIC SURGERY PATIENTS IN NORTH AMERICA, EUROPE AND OTHER COUNTRIES: LESSONS FROM THE FONDAPARINUX DATABASE (2004) (0)
- Proceedings of the National Heart, Lung, and Blood Institute Workshop on Hemostasis, Thrombosis, and Cardiovascular Diseases. Overview and research opportunities. (1992) (0)
- Enoxaparin thrombophylaxis did not reduce mortality in acutely ill medical patients (2012) (0)
- Site in the Factor VII Promoter Severe Factor VII Deficiency Due to a Mutation Disrupting an Sp1 Binding (2010) (0)
- myocardial infarction without altering von Willebrand Factor multimer size The thrombospondin-1 N700S polymorphism is associated with early (2013) (0)
- Fibrinogen Ledyard (Adrg,, + Cys): Biochemical and Physiologic Characterization (2003) (0)
- Molecular genetics of inherited factor VII deficiencies (1999) (0)
- Low Molecular Weight Heparin to Achieve Live Birth Following Unexplained Pregnancy Loss: A Meta-Analysis. (2009) (0)
- O3382 THE USE OF REGIONAL ANESTHESIA IN MAJOR ORTHOPAEDIC SURGERY (2004) (0)
- Title Page / Table of Contents, Vol. 26, Supplement 1, 1996 (1996) (0)
- Should You Treat This Acutely Ill Medical Inpatient With Venous Thromboembolism Chemoprophylaxis? (2020) (0)
- The Biologic Impact of Hereditary Defects that Cause Thrombosis (1991) (0)
- Abstract: 522 FVII, FVIIA AND DOWNSTREAM MARKERS OF EXTRINSIC PATHWAY ACTIVATION DIFFER BY EPCR SER219GLY VARIANT IN HEALTHY MEN (2009) (0)
- Transient decrease of thrombin generation during hirudin treatment in patients with acute coronary syndromes (1998) (0)
- THROMBOPROPHYLAXIS AFTER ORTHOPAEDIC SURGERY WITH BAY 59-7939–AN ORAL, DIRECT FACTOR XA INHIBITOR: (2008) (0)
- syndromes Coagulation activation and long-term outcome in acute coronary (2013) (0)
- Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders. (2002) (0)
- Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII) (2008) (0)
- Hypercoagulable states (2005) (0)
- Future Prospects in the Management of Acute Coronary Syndrome and Thrombosis (2006) (0)
- Thrombophilia evaluation: the value of testing relatives. (2010) (0)
- In Memoriam: Professor Robert Daniel Rosenberg, 1937-2020. (2020) (0)
- The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism—ATVB In Focus (2005) (0)
- The clinical spectrum of heterozygous protein C deficiency in a large New (2011) (0)
- ANTITHROMBIN III CONCENTRATE (AT-III) FOR PROPHYLAXIS ANDTREATMENT OF CONGENITAL AND ACQUIREDAT-III DEFCIENCY (1987) (0)
- Negative D-dimer Not Sufficient to Stop Anticoagulation in Men (2019) (0)
- The Thrombospondin-1 N700S Polymorphism Does Not Alter von Willebrand Factor Multimer Size in Patients Suffering an Acute Myocardial Infarction. (2005) (0)
- Report of the 2008 ASHP Task Force on Science. (2009) (0)
- Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS) (2003) (0)
- O1066 FONDAPARINUX IS SUPERIOR TO ENOXAPARIN FOR THROMBOPROPHYLAXIS IN ORTHOPEDIC SURGERY IRRESPECTIVE OF PATIENTS OR SURGERY CHARACTERISTICS (2004) (0)
- [Treatment and prevention of thrombotic episodes with hereditary thrombophilia]. (1997) (0)
- Fondaparinux. (2020) (0)
- Extrapulmonary manifestations of COVID-19 (2020) (0)
- Abnormal Factor Vil Coagulant Antigen in Patients with Renal Dysfunction and in Those with Disseminated Intravascular Coagulation (2013) (0)
- Diagnosis of myocardial disease or stroke using factor ix activation peptide (1999) (0)
- NONANTICOAGULANT INTERVENTIONS IN Thrombolytic therapy in acute venous thromboembolism (2020) (0)
- Congenital thrombophilia and venous disease (2006) (0)
- Development of Venous Thromboembolic Events in Cancer Patients with Elevated Levels of Tissue Factor-Bearing Microparticles (2008) (0)
- CP-ACPJ210009 1..12 (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kenneth A. Bauer?
Kenneth A. Bauer is affiliated with the following schools: